Cargando…
Inhaled corticosteroids for outpatients with COVID-19: a meta-analysis
The role of inhaled corticosteroids for outpatient COVID-19 is evolving. Meta-analysis of reported clinical trials estimated probability of any effect for symptom resolution by day 14 at 100% and hospitalisation at 89.3%, respectively. https://bit.ly/3B2sDUi
Autores principales: | Lee, Todd C., Bortolussi-Courval, Émilie, Belga, Sara, Daneman, Nick, Chan, Adrienne K., Hanula, Ryan, Ezer, Nicole, McDonald, Emily G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068973/ https://www.ncbi.nlm.nih.gov/pubmed/35144994 http://dx.doi.org/10.1183/13993003.02921-2021 |
Ejemplares similares
-
Evaluation of Oseltamivir Used to Prevent Hospitalization in Outpatients With Influenza: A Systematic Review and Meta-analysis
por: Hanula, Ryan, et al.
Publicado: (2023) -
Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis
por: Lee, Todd C., et al.
Publicado: (2022) -
Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a randomised controlled trial
por: Milne, Stephen, et al.
Publicado: (2021) -
Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial
por: Ezer, Nicole, et al.
Publicado: (2021) -
Drug Interactions With Nirmatrelvir-Ritonavir in Older Adults Using Multiple Medications
por: Ross, Sydney B., et al.
Publicado: (2022)